235 related articles for article (PubMed ID: 25422422)
1. Mechanism of ganciclovir-induced chain termination revealed by resistant viral polymerase mutants with reduced exonuclease activity.
Chen H; Beardsley GP; Coen DM
Proc Natl Acad Sci U S A; 2014 Dec; 111(49):17462-7. PubMed ID: 25422422
[TBL] [Abstract][Full Text] [Related]
2. Resistance to a Nucleoside Analog Antiviral Drug from More Rapid Extension of Drug-Containing Primers.
Chen H; Lawler JL; Filman DJ; Hogle JM; Coen DM
mBio; 2021 Feb; 12(1):. PubMed ID: 33563814
[TBL] [Abstract][Full Text] [Related]
3. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
Cihlar T; Fuller MD; Mulato AS; Cherrington JM
Virology; 1998 Sep; 248(2):382-93. PubMed ID: 9721246
[TBL] [Abstract][Full Text] [Related]
4. Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.
Chou S; Marousek G; Bowlin TL
Antimicrob Agents Chemother; 2012 Jan; 56(1):197-201. PubMed ID: 21968367
[TBL] [Abstract][Full Text] [Related]
5. Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility.
Piret J; Goyette N; Eckenroth BE; Drouot E; Götte M; Boivin G
J Virol; 2015 Apr; 89(8):4636-44. PubMed ID: 25673718
[TBL] [Abstract][Full Text] [Related]
6. Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility.
Chou S
Antiviral Res; 2021 Nov; 195():105181. PubMed ID: 34560144
[TBL] [Abstract][Full Text] [Related]
7. Comparison of human cytomegalovirus DNA polymerase activity for ganciclovir-resistant and -sensitive clinical strains.
Kariya M; Mori S; Eizuru Y
Antiviral Res; 2000 Feb; 45(2):115-22. PubMed ID: 10809020
[TBL] [Abstract][Full Text] [Related]
8. Exonuclease-polymerase active site partitioning of primer-template DNA strands and equilibrium Mg2+ binding properties of bacteriophage T4 DNA polymerase.
Beechem JM; Otto MR; Bloom LB; Eritja R; Reha-Krantz LJ; Goodman MF
Biochemistry; 1998 Jul; 37(28):10144-55. PubMed ID: 9665720
[TBL] [Abstract][Full Text] [Related]
9. Potency and Stereoselectivity of Cyclopropavir Triphosphate Action on Human Cytomegalovirus DNA Polymerase.
Chen H; Li C; Zemlicka J; Gentry BG; Bowlin TL; Coen DM
Antimicrob Agents Chemother; 2016 Jul; 60(7):4176-82. PubMed ID: 27139481
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of ganciclovir-resistant cytomegalovirus].
Eizuru Y
Nihon Rinsho; 1998 Jan; 56(1):151-5. PubMed ID: 9465681
[TBL] [Abstract][Full Text] [Related]
11. Contribution of the 3'- to 5'-exonuclease activity of herpes simplex virus type 1 DNA polymerase to the fidelity of DNA synthesis.
Song L; Chaudhuri M; Knopf CW; Parris DS
J Biol Chem; 2004 Apr; 279(18):18535-43. PubMed ID: 14982924
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
Scott GM; Weinberg A; Rawlinson WD; Chou S
Antimicrob Agents Chemother; 2007 Jan; 51(1):89-94. PubMed ID: 17043128
[TBL] [Abstract][Full Text] [Related]
13. Rapid detection and quantitation of ganciclovir resistance in cytomegalovirus quasispecies.
Ruiz-Carrascoso G; Romero-Gómez MP; Plaza D; Mingorance J
J Med Virol; 2013 Jul; 85(7):1250-7. PubMed ID: 23592041
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.
Sánchez Puch S; Ochoa C; Carballal G; Zala C; Cahn P; Brunet R; Salomón H; Videla C
J Clin Virol; 2004 Jul; 30(3):271-5. PubMed ID: 15135748
[TBL] [Abstract][Full Text] [Related]
15. Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase.
Mousavi-Jazi M; Schloss L; Wahren B; Brytting M
J Clin Virol; 2003 Apr; 26(3):301-6. PubMed ID: 12637079
[TBL] [Abstract][Full Text] [Related]
16. Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir.
Bounaadja L; Piret J; Goyette N; Boivin G
J Clin Virol; 2013 Sep; 58(1):279-82. PubMed ID: 23871165
[TBL] [Abstract][Full Text] [Related]
17. Human herpesvirus 6 ganciclovir-resistant strain with amino acid substitutions associated with the death of an allogeneic stem cell transplant recipient.
Isegawa Y; Hara J; Amo K; Osugi Y; Takemoto M; Yamanishi K; Fukunaga R; Shibata M; Ohshima A; Horiguchi Y; Sugimoto N
J Clin Virol; 2009 Jan; 44(1):15-9. PubMed ID: 18952495
[TBL] [Abstract][Full Text] [Related]
18. Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance.
Göhring K; Mikeler E; Jahn G; Rohde F; Hamprecht K
Antivir Ther; 2008; 13(3):461-6. PubMed ID: 18572760
[TBL] [Abstract][Full Text] [Related]
19. Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase.
Tenney DJ; Yamanaka G; Voss SM; Cianci CW; Tuomari AV; Sheaffer AK; Alam M; Colonno RJ
Antimicrob Agents Chemother; 1997 Dec; 41(12):2680-5. PubMed ID: 9420038
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation.
Göhring K; Wolf D; Bethge W; Mikeler E; Faul C; Vogel W; Vöhringer MC; Jahn G; Hamprecht K
J Clin Virol; 2013 May; 57(1):43-9. PubMed ID: 23375740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
